New clotting drug may cut bleeding in rare cancer surgery
NCT ID NCT06617897
First seen Apr 05, 2026 · Last updated May 12, 2026 · Updated 7 times
Summary
This study tests a medicine called fibrinogen concentrate (CSL511) to see if it controls bleeding better than the standard treatment (cryoprecipitate) during surgery for pseudomyxoma peritonei, a rare abdominal cancer. About 90 adults will be randomly assigned to receive one of the two treatments during their operation. The goal is to improve blood clotting and reduce the need for blood transfusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED FIBRINOGEN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Basingstoke and North Hampshire Hospital
RECRUITINGBasingstoke, RG24 9NA, United Kingdom
Contact
Conditions
Explore the condition pages connected to this study.